Literature DB >> 19146896

Mucosal immunity in mice induced by orally administered transgenic rice.

Xiuxiang Zhang1, Ziguo Yuan, Qing Duan, Hong Zhu, Hui Yu, Qingyu Wang.   

Abstract

Transgenic plants are efficient means of producing and delivering oral vaccines. Rice material shown previously to express the Chlamydophila psittaci (Cp. psittaci) antigen (MOMP) fused to the B subunit of Escherichia coli heat-labile enterotoxin (LTB) was fed to mice and the resulting immune response was investigated. Oral immunization of mice with the transgenic rice elicited MOMP-specific sera IgG and IgA antibodies, a strong increase of the lymphoproliferative response, and significant levels of IFN-gamma, TGF-beta and IL-2 production. Furthermore, the immunization of mice with transgenic rice elicited strong cytotoxic T lymphocyte (CTL) responses in vitro. These results demonstrated that plant-made LTB-MOMP fusion protein could induce significant humoral and cellular Th1 and Th3 immune responses. Moreover, transgenic rice immunization induced partial protection (53.3%) against a lethal challenge with the highly virulent Cp. psittaci 6BC strain in a BALB/c mouse model. These results suggest that expression of protective antigens of Cp. psittaci in transgenic rice has potential as an edible vaccine against avain chlamydiosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146896     DOI: 10.1016/j.vaccine.2008.12.042

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis.

Authors:  M M Liu; Z G Yuan; G H Peng; D H Zhou; X H He; C Yan; C C Yin; Y He; R Q Lin; H Q Song; X Q Zhu
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

2.  Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in mice.

Authors:  Zi-Guo Yuan; Xiu-Xiang Zhang; Xian-Hui He; Eskild Petersen; Dong-Hui Zhou; Yong He; Rui-Qing Lin; Xiu-Zhen Li; Xu-Li Chen; Xiao-Ru Shi; Xiu-Ling Zhong; Bing Zhang; Xing-Quan Zhu
Journal:  Clin Vaccine Immunol       Date:  2010-11-24

3.  Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice.

Authors:  Melina Laguía-Becher; Valentina Martín; Mauricio Kraemer; Mariana Corigliano; María L Yacono; Alejandra Goldman; Marina Clemente
Journal:  BMC Biotechnol       Date:  2010-07-15       Impact factor: 2.563

4.  LTB-Syn: a recombinant immunogen for the development of plant-made vaccines against synucleinopathies.

Authors:  Jaime I Arevalo-Villalobos; Dania O Govea-Alonso; Elizabeth Monreal-Escalante; Sergio Zarazúa; Sergio Rosales-Mendoza
Journal:  Planta       Date:  2017-03-17       Impact factor: 4.116

5.  Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge.

Authors:  Zonghui Zuo; Yongjuan Zou; Qiang Li; Yongxia Guo; Tianyuan Zhang; Jie Wu; Cheng He; Francis O Eko
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

Review 6.  AB toxins: a paradigm switch from deadly to desirable.

Authors:  Oludare Odumosu; Dequina Nicholas; Hiroshi Yano; William Langridge
Journal:  Toxins (Basel)       Date:  2010-06-25       Impact factor: 4.546

7.  Comparison of the immune responses induced by oral immunization of mice with Lactobacillus casei-expressing porcine parvovirus VP2 and VP2 fused to Escherichia coli heat-labile enterotoxin B subunit protein.

Authors:  Diqiu Liu; Xiangqing Wang; Junwei Ge; Songmei Liu; Yijing Li
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2010-03-11       Impact factor: 2.268

Review 8.  Improving pharmaceutical protein production in Oryza sativa.

Authors:  Yu-Chieh Kuo; Chia-Chun Tan; Jung-Ting Ku; Wei-Cho Hsu; Sung-Chieh Su; Chung-An Lu; Li-Fen Huang
Journal:  Int J Mol Sci       Date:  2013-04-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.